 Shares of Ascendis Pharma AS NASDAQ:ASND have earned a consensus rating of Buy from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month ... 